Free US stock ESG scoring and sustainability analysis for responsible investing considerations. We evaluate environmental, social, and governance factors that increasingly impact long-term company performance.
This analysis covers the April 24, 2026 announcement that Bristol Myers Squibb (NYSE: BMY) and co-marketing partner Pfizer (NYSE: PFE) will list their top-selling anticoagulant Eliquis on the Mark Cuban Cost Plus Drug Company (MCCPDC) platform starting the following week, priced at $345 for a 30-day
Bristol Myers Squibb (BMY) - Partners With Pfizer to List Blockbuster Anticoagulant Eliquis on Mark Cuban Cost Plus Platform at $345 Monthly - Bond Issuance
BMY - Stock Analysis
4354 Comments
719 Likes
1
Apostolos
Experienced Member
2 hours ago
Really wish I had known before.
👍 188
Reply
2
Cateria
Trusted Reader
5 hours ago
Anyone else trying to connect the dots?
👍 17
Reply
3
Hazely
Consistent User
1 day ago
Strong sector rotation is supporting overall index performance.
👍 267
Reply
4
Aveona
Experienced Member
1 day ago
Anyone else watching this unfold?
👍 224
Reply
5
Litzzy
Community Member
2 days ago
Comprehensive US stock technology adoption analysis and competitive moat durability assessment for innovation-driven industries. We evaluate whether companies can maintain their technological advantages against fast-moving competitors.
👍 102
Reply
© 2026 Market Analysis. All data is for informational purposes only.